Tina Bhutani-Jacques, MD

In the concluding episode, Dr. Tina Bhutani-Jacques emphasizes the importance of looking beyond clinical measures such as body surface area when evaluating treatment success in patients with plaque psoriasis.

In the concluding segment, Dr. Tina Bhutani-Jacques discusses the rationale for initiating tapinarof 1% cream in a patient with localized plaque psoriasis who is unwilling to use topical corticosteroids because of concerns about long-term adverse effects.

In the discussion, Dr. Tina Bhutani-Jacques reviews the management of a 34-year-old man with localized plaque psoriasis who is seeking effective long-term disease control while avoiding topical corticosteroids.

In the third case, Dr. Tina Bhutani-Jacques introduces a 34-year-old man with longstanding plaque psoriasis involving approximately 2% body surface area who remains frustrated by recurrent flares and visible plaques despite previous treatment with topical corticosteroids.

In this segment, Dr. Tina Bhutani-Jacques expands on the rationale for selecting roflumilast 0.3% foam for a patient with plaque psoriasis affecting both the scalp and body.

In this episode, Dr. Tina Bhutani-Jacques presents the second case, featuring a 45-year-old woman with plaque psoriasis affecting both the scalp and body.

In this segment, Dr. Tina Bhutani-Jacques discusses the clinical rationale for transitioning patients with plaque psoriasis to newer nonsteroidal topical therapies when previous treatments have provided inadequate efficacy or tolerability.

A 48-year-old man with chronic plaque psoriasis develops new intertriginous involvement unresponsive to prior topical regimens. Dr. Bhutani-Jacques outlines how lesion location and treatment history inform selection of a non-steroidal topical agent.

Despite advances in systemic and biologic therapy, topical agents remain the primary treatment for most patients with plaque psoriasis. Dr. Bhutani-Jacques reviews the steroidal and non-steroidal armamentarium and the risks associated with prolonged corticosteroid use.

Tina Bhutani, MD, MAS, highlights emerging topical treatments for pediatric atopic dermatitis, emphasizing improved adherence in younger children, the potential impact of ruxolitinib FDA approval for ages 2 and up, and the promise of ongoing trials in infants under 2 years.

Tina Bhutani, MD, MAS, discusses innovative pediatric atopic dermatitis treatments, including ruxolitinib cream, emphasizing collaborative decision-making for effective management.

Dr Bhutani presents the case of a 15-year-old female with long standing atopic dermatitis and discusses the importance of balancing parental preferences for "natural" agents with effective pharmaceutical options. She also reviews the significance of patient assistance programs in facilitating patient access to and affordability of pharmaceutical therapies.

Tina Bhutani-Jacques, MD, presents the case of a 28-year old male with atopic dermatits, wherein the patient attributes his flares to his housing conditions. She discusses the role of patient counseling, shared decision making, and sustained disease control in the management of patients suffering from this condition.